:

Does GLP-1 Slow Down Aging? Examining the Science Behind Longevity

A 2025 clinical trial on individuals with HIV-associated lipohypertrophy found that semaglutide stabilized epigenetic aging, offering a new perspective on whether **GLP-1 slows down aging**. This has sparked significant interest in the longevity field, moving beyond GLP-1's primary metabolic effects to explore its broader potential to impact the aging process.